Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study

@article{Finkel2017TreatmentOI,
  title={Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study},
  author={Richard S. Finkel and Claudia A. Chiriboga and Jiri Vajsar and John W. Day and Jacqueline Montes and Darryl C. de Vivo and Mason Yamashita and Frank Rigo and Gene Hung and Eugene Schneider and Daniel A Norris and Shuting Xia and C. Frank Bennett and Kathie M. Bishop},
  journal={The Lancet},
  year={2017},
  volume={388},
  pages={3017-3026}
}

Figures and Tables from this paper

Current evidence for treatment with nusinersen for spinal muscular atrophy: a systematic review

TLDR
Results are hopeful with significant and clinically meaningful improvement due to treatment with intrathecal nusinersen in patients with early- and later-onset spinal muscular atrophy, although this does not restore age-appropriate function.

Nusinersen in patients older than 7 months with spinal muscular atrophy type 1

TLDR
The results are in line with the phase 3 study for nusinersen in patients with SMA1 treated before 7 months of age and indicate that patients benefit from nusineren even at a later stage of the disease.

Current evidence for treatment with nusinersen for spinal muscular atrophy: a systematic review

TLDR
Investigation of the current evidence for treatment with intrathecal nusinersen in patients with spinal muscular atrophy found it has acceptable safety and tolerability, although this does not restore age-appropriate function.

Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US

TLDR
The estimated incremental cost-effectiveness of nusinersen from a US health care sector perspective exceeded traditional cost-effective thresholds and was most sensitive to the length of survival, background health care costs, and utility in the “not sitting” and “sitting” health states.

Nusinersen versus Sham Control in Infantile‐Onset Spinal Muscular Atrophy

TLDR
Those who received nusinersen were more likely to be alive and have improvements in motor function than those in the control group and infants with a shorter disease duration at screening wereMore likely than those with a longer disease duration to benefit from nusineren.

Nusinersen: A Treatment for Spinal Muscular Atrophy

TLDR
Nusinersen is safe and effective in patients with SMA and was well tolerated across all studied age groups, according to phase III trial data.

Nusinersen in later-onset spinal muscular atrophy

TLDR
Nusinersen treatment over ∼3 years resulted in motor function improvements and disease activity stabilization not observed in natural history cohorts, document the long-term benefit of nusineren in later-onset SMA, including SMA type III.
...

References

SHOWING 1-10 OF 37 REFERENCES

Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy

TLDR
This study provides Class IV evidence that in children with SMA, intrathecal nusinersen is not associated with safety or tolerability concerns, and support continued development of nusineren for treatment of SMA.

Genotype–phenotype studies in infantile spinal muscular atrophy (SMA) type I in Germany: implications for clinical trials and genetic counselling

TLDR
The observed clinical variability, especially in the group with two SMN2 copies, might be important for clinical trials in SMA I where a possible control group could be defined as follows: age at onset within 4–5 months, age at genetic diagnosis <6 months, two SMn2 copies present, head control in less than 10%, no respiratory distress from birth, disease endpoint either age at death or age at permanent ventilation.

Observational study of spinal muscular atrophy type I and implications for clinical trials

TLDR
Infants with SMA-I can be effectively enrolled and retained in a 12-month natural history study until a majority reach the combined endpoint of death, and these outcome data can be used for clinical trial design.

Spinal muscular atrophy: Diagnosis and management in a new therapeutic era

TLDR
An update is provided regarding the most common form of SMA, proximal or 5q‐SMA, and the contemporary approach to diagnosis and treatment and several promising therapeutics are now being tested in early‐phase clinical trials.

Intrathecal Injections in Children With Spinal Muscular Atrophy

TLDR
Lumbar puncture–related adverse event frequency was similar to that previously reported in children, and adverse events were more frequent in older children, children with type 3 spinal muscular atrophy, and with a 21- or 22-gauge needle compared to a 24-g Gauge needle or smaller.

Correlation between severity and SMN protein level in spinal muscular atrophy

TLDR
A marked deficiency of the SMN protein in SMA is shown and the molecular mechanism underlying the pathogenesis of the disease is elucidated by western blot and immunohistochemical analyses using antibodies raised against theSMN protein.

Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications.

TLDR
The definition of long-term characteristics of SMA is helpful in providing medical care to families with members who have SMA and also in providing important information for future genotype-phenotype studies and therapeutic trials of patients with SMA.

Spinal muscular atrophy type 1: Are proactive respiratory interventions associated with longer survival?

TLDR
Longer survival time with spinal muscular atrophy type 1 is associated with early, noninvasive respiratory care interventions after diagnosis, and these interventions were grouped according to the level of respiratory support their caregivers chose within the first 3 months after diagnosis.

An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA)

TLDR
Given this uniform mutation spectrum, direct molecular genetic testing is an easy and rapid analysis for most of the SMA patients, and direct testing of heterozygotes, while not trivial, is compromised by the presence of two SMN1 copies per chromosome in about 4% of individuals.